Order byBest matchMost fresh

Lilly sues 2 compounders over copies of weight-loss drugs

Digest more
Top News
Impacts
Lilly said Strive's tirzepatide products, which come in standard doses added with vitamin B12 or glycine, are falsely suggested to be safer and more effective than FDA-approved medicines.
From Reuters
Moreover, Bank of America also published bearish guidance, given that the company is expected to stop compounded semaglutide drug sales by May 22nd.
From Business Insider

Read more on News Digest

Lilly sues two compounders over copies of weight-loss drugs
Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ingredient in its popular weight-loss and diabetes medicines.
Eli Lilly Vs. Hims & Hers In DTC Weight Loss Market? - There Is Only One Winner
Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges. Find out who is the winner.
DTC obesity med market heats up: Eli Lilly taps knownwell, Hims & Hers adds new weight loss meds to platform
Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as generics of Novo Nordisk's diabetes drug liraglutide through its weight loss platform.
‘Too Hot to Handle,’ Analyst Warning on Hims & Hers Health Stock (HIMS)
Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads. With sales
Zepbound Now Available Through Hims & Hers
Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers. With insurance,
Why April Could Be a Huge Month for Eli Lilly Stock
A key drug that investors are going to be following this year is orforglipron, a once-daily pill that Eli Lilly is developing for weight loss and other indications. The early data has been encouraging,
Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaro
Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and Mounjaro.
Jim Cramer Says You Should ‘Stay Long’ Eli Lilly (LLY) Because of These Reasons
We recently published a list of Jim Cramer Was Talking About These 10 Stocks Amid Trump’s Trade Wars. In this article, we are going to take a look at where Eli Lilly (NYSE:LLY) stands against other stocks that Jim Cramer was talking about amid Trump’s trade wars.
Eli Lilly weight loss therapy added to Hims & Hers platform (update)
Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic liraglutide to its platform. Read more here.
Medscape1h
Switching to Tirzepatide Outweighs Upping Dulaglutide Dose
The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.
Hims & Hers to Sell Lilly's Weight-Loss Drug on Its Telehealth Platform
(Reuters) -Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly's weight-loss drug Zepbound on its platform. Shares of the company were up 8.5% in afternoon trading. Copyright 2025 Thomson Reuters.
Explore more
Nasdaq2d
Eli Lilly Sues Pharmacies Over Unauthorized Tirzepatide Compounding
(RTTNews) - Eli Lilly And Co. (LLY) filed lawsuits Tuesday against Strive Pharmacy and Empower Pharmacy, accusing them of unlawfully compounding and selling tirzepatide, the active ingredient in ...
Where Will Eli Lilly Be in 1 Year?
Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 agonists could be evolving, and Eli Lilly has a high-stakes opportunity to dominate it over the coming year.
Citi sees high price of Tirzepatide on Hims & Hers being ‘prohibitive’
Citi analyst Daniel Grosslight says Hims & Hers traded up 10% yesterday after Bloomberg noted the company is now offering branded
Eli Lilly threatens Zepbound copycat makers after shortage, Bloomberg reports
Eli Lilly (LLY) is targeting additional drug compounders and telehealth companies that make copycat versions of its weight loss drug, with
Feedback